General Atlantic Weighs $2 Billion Sale of OneOncology

General Atlantic is exploring the sale of OneOncology, an operator of independent cancer-care practices, according to people with knowledge of the matter.

(Bloomberg) — General Atlantic is exploring the sale of OneOncology, an operator of independent cancer-care practices, according to people with knowledge of the matter.

The growth equity-focused investment firm, which has backed OneOncology since 2018, is working with an adviser to solicit interest in the Nashville, Tennessee-based company, which could fetch more than $2 billion including debt in a sale, said the people, who asked not to be identified discussing confidential information. 

A General Atlantic spokeswoman declined to comment. A OneOncology representative didn’t immediately respond to a request for comment.

OneOncology, led by Chief Executive Officer Jeff Patton, aims to provide patients with cost-effective and high-quality care close to home, according to its website. Its care providers work from more than 175 sites in states including New York, Louisiana and California, according to a December statement.  

Other alternative-investment firms have made bets in the oncology space, including KKR & Co., which owns a stake in GenesisCare.

More stories like this are available on bloomberg.com

©2023 Bloomberg L.P.